OTCMKTS:SWTUY SWEDISH ORPHAN/S (SWTUY) Stock Price, News & Analysis $24.38 -0.29 (-1.18%) As of 04/9/2019 Add Compare Share Share Stock Analysis Stock Analysis About SWEDISH ORPHAN/S Stock (OTCMKTS:SWTUY) Get SWEDISH ORPHAN/S alerts:Sign Up Key Stats Today's Range$24.38▼$24.3850-Day Range$24.38▼$24.3852-Week Range$18.50▼$31.96Volume200 shsAverage Volume1,665 shsMarket Capitalization$6.64 billionP/E Ratio48.76Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Swedish Orphan Biovitrum AB, known as Sobi, is a Sweden-based specialty pharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. The company’s primary therapeutic areas include hematology, immunology and other conditions with significant unmet medical needs. Sobi’s portfolio includes treatments for inherited and acquired blood disorders, immune-mediated diseases and related specialty-care conditions. Its products and development programs are distributed across international markets, with commercial activities spanning Europe, North America and selected regions in the Middle East, Asia and other global markets. The company traces its roots to Swedish pharmaceutical operations established in the 1930s and adopted its current name after Swedish Orphan International combined with Biovitrum in 2010. Sobi is headquartered in Stockholm, Sweden, and operates through a combination of internal research and development, manufacturing partnerships and collaborations with biotechnology and pharmaceutical companies.AI Generated. May Contain Errors. Read More Receive SWTUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SWEDISH ORPHAN/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SWTUY Stock News HeadlinesSwedish Orphan Biovitrum AB: New analysis shows Tryngolza (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemiaMay 26, 2026 | finanznachrichten.deSwedish Orphan Biovitrum Receives Health Canada Approval for EMPAVELI (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGNApril 28, 2026 | finanznachrichten.deALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Swedish Orphan Biovitrum AB: EMA validates indication extension application for Tryngolza (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)March 31, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026February 3, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi Receives European Commission Approval for Aspaveli (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGNJanuary 16, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlookJanuary 15, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB completes key study on Still’s disease in ItalyDecember 14, 2025 | msn.comSee More Headlines SWTUY Stock Analysis - Frequently Asked Questions How have SWTUY shares performed this year? SWEDISH ORPHAN/S's stock was trading at $24.38 at the start of the year. Since then, SWTUY shares have increased by 0.0% and is now trading at $24.38. How do I buy shares of SWEDISH ORPHAN/S? Shares of SWTUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:SWTUY Previous SymbolNASDAQ:SWTUY CIKN/A Webwww.sobi.com Phone46-0-869-720-00FaxN/AEmployees902Year Founded2010Profitability EPS (Trailing Twelve Months)$0.50 Trailing P/E Ratio48.76 Forward P/E RatioN/A P/E Growth1.3Net Income$134.73 million Net Margins25.75% Pretax MarginN/A Return on Equity29.63% Return on Assets18.74% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$763.19 million Price / Sales8.71 Cash Flow$0.70 per share Price / Cash Flow34.66 Book Value$2.88 per share Price / Book8.47Miscellaneous Outstanding Shares272,508,000Free FloatN/AMarket Cap$6.64 billion OptionableNot Optionable Beta1.81 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:SWTUY) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SWEDISH ORPHAN/S Please log in to your account or sign up in order to add this asset to your watchlist. Share SWEDISH ORPHAN/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
